Generic Name and Formulations:
Dexmethylphenidate HCl (single-isomer methylphenidate) 2.5mg, 5mg, 10mg+; tabs; +dye-free.
Novartis Pharmaceuticals Corp
Indications for FOCALIN:
Attention deficit hyperactivity disorder.
Adults and Children:
<6yrs: not established. Individualize. ≥6yrs: initially 2.5mg twice daily. Switching from racemic methylphenidate (eg, Ritalin): ½ of racemic methylphenidate dose. Allow at least 4 hours between doses. May increase by 2.5–5mg weekly; max 20mg/day.
Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family. During or within 14 days of MAOIs.
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. Caution with pressor agents. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), tricyclics (eg, imipramine, clomipramine, desipramine), SSRIs; adjust doses. May decrease effectiveness of antihypertensive agents. Caps: may be affected by drugs that affect pH (eg, antacids, acid suppressants). Risk of serotonin syndrome with serotonergic drugs.
Dyspepsia, dry mouth, decreased appetite, headache, anxiety, anorexia, insomnia, nausea, abdominal pain, weight loss; hypertension, tachycardia, visual disturbances, priapism.
XR 5mg, 10mg, 15mg, 20mg, 30mg, 40mg (YES); 25mg, 35mg (NO); tabs (YES)
XR caps, tabs—100
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder